Market overview

2,3-Dichloro-5-(trifluoromethyl)pyridine (2,3,5-DCTF, CAS 69045-84-7) is the most in-demand trifluoromethylpyridine intermediate. It is the building block for the fungicide fluazinam, the herbicide haloxyfop-methyl and the insect growth regulator chlorfluazuron, and via its amino derivative for the nematicide fluazaindolizine. Producers run liquid-phase chlorination of picolines followed by vapour-phase fluorination, a capital-intensive process with significant chlorinated by-product streams. Chinese and Indian capacity has grown as these active ingredients went generic.

The question this report answers
How much 2,3-dichloro-5-trifluoromethylpyridine do fluazinam, haloxyfop and fluopyram need, and can supply keep up?

Market Krystal preliminary estimate (2025)
No published size. As the most in-demand TFMP intermediate, we assume 5-10 kt at USD 10-20/kg, giving USD 50-200 mn. Confidence grade C: no reliable published figure; range built from the stated assumptions and narrowed in the full report.

Market dynamics
– Demand: fluazinam, haloxyfop-methyl, chlorfluazuron, fluopyram and fluazaindolizine
– Supply: Chinese producers dominate, plus Ishihara Sangyo
– Price and margin: cyclical with Chinese agrochemical destocking
– Regulation: agrochemical registrations; Chinese environmental inspections

Key figures at a glance (third-party, cited)
– 22 TFMP-containing agrochemicals have ISO common names; five TFMP pharmaceuticals and two veterinary products are approved (Ishihara Sangyo authors, J. Pestic. Sci. 2021)
– Picoxystrobin sells over 2,000 t/yr; fluopicolide and fluopyram together about 1,000 t/yr (J. Pestic. Sci. 2021)
– 2,3,5-DCTF is the most in-demand TFMP intermediate, used for fluazinam, haloxyfop-methyl, chlorfluazuron and fluazaindolizine (J. Pestic. Sci. 2021)

Recent developments among key stakeholders
– Jul 2025: China’s pesticide sector is consolidating; environmental inspections are limiting production windows, smaller producers are exiting, and the collapse of mutual data acceptance is pushing Chinese firms to costlier third-country GLP labs, lengthening registrations (AgroSpectrum)
– Demand context: picoxystrobin sells over 2,000 t/yr and fluopicolide plus fluopyram about 1,000 t/yr, the largest TFMP outlets (J. Pestic. Sci. 2021)

What this means for the market
TFMP intermediates depend on Chinese and Indian vapour-phase capacity, which is consolidating under environmental pressure. The report maps who will remain a reliable supplier.

How published estimates compare
Generic market listings for 2,3,5-DCTF rarely connect volume to the active ingredients it makes. Market Krystal models demand from fluazinam, haloxyfop and chlorfluazuron production, plus new actives, and compares it with announced Chinese and Indian capacity.

Strategic scenarios to 2047
– Base: crop-protection and generic-drug volumes grow with food demand and patent expiries; intermediates follow their downstream actives, with China and India as main producers.
– Constrained supply: Chinese environmental inspections, export restrictions or Western ‘China-plus-one’ rules tighten intermediate supply; qualified Indian and Western sources gain share and pricing.
– Technology transition: new actives, biologicals and regulatory bans retire older molecules, so demand for a given intermediate can fall sharply when its downstream product loses registration or patent protection.
The swing factor for 2,3-Dichloro-5-trifluoromethylpyridine is fluazinam, haloxyfop and fluopyram registrations. Signposts: EU and US re-registration decisions, patent expiries, Chinese production curbs, India PLI investments.

What this report delivers
Annual volume (tonnes) and value (USD) for 2026-2035, segmented by application: fluazinam, haloxyfop-methyl/haloxyfop-P, chlorfluazuron, fluazaindolizine, other; region: China, India, Japan, demand in Americas and Asia. Each segment is backed by a producer capacity table, price benchmarks for 2020-2025 by grade and region, trade-flow analysis and a supplier risk map. Companies assessed include Ishihara Sangyo Kaisha, Lier Chemical, Zhejiang Yongtai, Jubilant Ingrevia, Corteva (fluazaindolizine), Chinese TFMP producers. The 2036-2047 outlook uses three explicit scenarios (base, constrained supply and technology transition) rather than a single extrapolated curve.

Who uses this report
Agrochemical and pharmaceutical process teams, CDMOs, intermediate producers in India and China, and sourcing managers.

Why our approach is evidence-based
Most CAS-level market listings publish a single number with no audit trail, and we regularly find figures that contradict their own growth rates or exceed the size of the market they sit inside. Market Krystal works the other way round. We start from physical evidence: plant capacities, production and trade data, company disclosures, regulatory texts and price records. We build volume and price separately and only then compute value. Every third-party figure is cited, every Market Krystal estimate is labelled with its method and a confidence grade, and conflicts between sources are shown rather than hidden. Confidence grades: A = two or more independent sources agree, or government or company data; B = one published estimate checked against volumes or prices; C = no reliable published figure, so the range is built from stated assumptions and narrowed in the full report.

Methodology and delivery
Prepared by the Market Krystal Chemicals Research Team. Each report is built around the buyer’s question: after purchase, a short scope confirmation fixes the priority regions, companies and applications, and the report is delivered within 5-7 business days with the Excel model behind every estimate, so buyers can audit and change the assumptions.

The purchased delivery includes the PDF report, Excel datasets and customization around the buyer’s priority region, company set, application or commercial question.

What this research answers

The study connects production routes, named suppliers, applications, regional demand, trade, pricing drivers and commercial opportunities for this CAS number. Detailed estimates and company analysis remain inside the purchased report.